Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nimodipine, quantity: 0.2 mg/ml - injection, intravenous infusion - excipient ingredients: ethanol; macrogol 400; sodium citrate dihydrate; citric acid; water for injections - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus (eg hunt and hess grades i-iii).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; hydroxypropylbetadex; purified water; flavour; sorbitol; methyl hydroxybenzoate; citric acid; sucrose; glycerol; monobasic sodium phosphate; potassium sorbate - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; colloidal anhydrous silica; povidone - women: moderately severe to severe signs of androgenization. moderately severe/severe forms of hirsutism.moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization.cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.if androcur is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation.men:reduction of drive in sexual deviations androcur reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a pre-requisite for therapy is the desire by the patient for treatment.androcur therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation.inoperable prostatic carcinoma to suppress "flare" with initial lhrh analogue therapy in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - norethisterone, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - dysfunctional bleeding, primary and secondary amenorrhoea, premenstrual syndrome, delay of menstrual period, endometriosis, adjunct to estrogen hormone replacement therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 2 mg - tablet, sugar coated - excipient ingredients: magnesium stearate; indigo carmine; macrogol 6000; sucrose; glycol montanate; titanium dioxide; calcium carbonate; povidone; maize starch; lactose monohydrate; glycerol; purified talc - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 1 mg - tablet, sugar coated - excipient ingredients: iron oxide yellow; glycerol; povidone; macrogol 6000; magnesium stearate; calcium carbonate; sucrose; titanium dioxide; glycol montanate; maize starch; purified talc; lactose monohydrate - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 125 microgram; ethinylestradiol, quantity: 50 microgram - tablet, sugar coated - excipient ingredients: calcium carbonate; magnesium stearate; purified talc; glycol montanate; lactose monohydrate; maize starch; macrogol 6000; sucrose; povidone - oral contraception

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, sugar coated - excipient ingredients: purified talc; lactose monohydrate; macrogol 6000; sucrose; povidone; magnesium stearate; calcium carbonate; maize starch; glycol montanate - oral contraception

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - bupivacaine hydrochloride; lignocaine as lignocaine hydrochloride; adrenaline-l-acid tartrate-d; cetrimide - topical cream, ointment, paste, gel, lotion - bupivacaine hydrochloride anaesthetic active 4.2 g/l; lignocaine as lignocaine hydrochloride anaesthetic active 40.6 g/l; adrenaline-l-acid tartrate-d hormone active 24.8 mg/l; cetrimide ammonium-quaternary active 5.0 g/l - anaesthetics/analgesics - lamb with mulesing wound - post surgical pain